| Sign In to gain access to subscriptions and/or personal tools. |
Novel In Vitro Protein Fragment Complementation Assay Applicable to High-Throughput Screening in a 1536-Well FormatBiomedicinal Information Research Center (BIRC), Japan Biological Informatics Consortium (JBIC), Tokyo, Japan
Biomedicinal Information Research Center (BIRC), Japan Biological Informatics Consortium (JBIC), Tokyo, Japan, Amalgaam Co., Ltd., Tokyo, Japan
Biomedicinal Information Research Center (BIRC), Japan Biological Informatics Consortium (JBIC), Tokyo, Japan, Amalgaam Co., Ltd., Tokyo, Japan
Biomedicinal Information Research Center (BIRC), Japan Biological Informatics Consortium (JBIC), Tokyo, Japan, Amalgaam Co., Ltd., Tokyo, Japan, Laboratory for Cell Function and Dynamics, Advanced Technology Development Group, Brain Science Institute, Saitama, Japan
Biomedicinal Information Research Center (BIRC), Japan Biological Informatics Consortium (JBIC), Tokyo, Japan
Biomedicinal Information Research Center (BIRC), Japan Biological Informatics Consortium (JBIC), Tokyo, Japan
Biomedicinal Information Research Center (BIRC), National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan
Biomedicinal Information Research Center (BIRC), National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan
Biomedicinal Information Research Center (BIRC), National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan
Biomedicinal Information Research Center (BIRC), National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan
Laboratory for Cell Function and Dynamics, Advanced Technology Development Group, Brain Science Institute, Saitama, Japan
Biomedicinal Information Research Center (BIRC), Japan Biological Informatics Consortium (JBIC), Tokyo, Japan, motoki-takagi{at}aist.go.jp
Biomedicinal Information Research Center (BIRC), National Institute of Advanced Industrial Science and Technology (AIST), Tokyo, Japan Protein-protein interactions (PPIs) play key roles in all cellular processes and hence are useful as potential targets for new drug development. To facilitate the screening of PPI inhibitors as anticancer drugs, the authors have developed a high-throughput screening (HTS) system using an in vitro protein fragment complementation assay (PCA) with monomeric Kusabira-Green fluorescent protein (mKG). The in vitro PCA system was established by the topological formation of a functional complex between 2 split inactive mKG fragments fused to target proteins, which fluoresces when 2 target proteins interact to allow complementation of the mKG fragments. Using this assay system, the authors screened inhibitors for TCF7/β-catenin, PAC1/PAC2, and PAC3 homodimer PPIs from 123,599 samples in their natural product library. Compound TB1 was identified as a specific inhibitor for PPI of PAC3 homodimer. TB1 strongly inhibited the PPI of PAC3 homodimer with an IC 50 value of 0.020 µM and did not inhibit PPI between TCF7/β-catenin and PAC1/PAC2 even at a concentration of 250 µM. The authors thus demonstrated that this in vitro PCA system applicable to HTS in a 1536-well format is capable of screening for PPI inhibitors from a huge natural product library. ( Journal of Biomolecular Screening 2009:970-979)
Key Words: protein fragment complementation assay bimolecular fluorescence complementation monomeric Kusabira-Green protein protein-protein interaction high-throughput screening
This version was published on September
1, 2009 Journal of Biomolecular Screening, Vol. 14, No. 8,
970-979 (2009) |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
